The risk of secondary acute myeloid leukemia (AML) among subjects with breast cancer receiving standard-dose cyclophosphamide and doxorubicin has been reported equivalent to that of the general population.
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer TO 
THE EDITOR
The risk of secondary acute myeloid leukemia (AML) among subjects with breast cancer receiving standard-dose cyclophosphamide and doxorubicin has been reported equivalent to that of the general population. 1 Recently an increased frequency of therapy-related leukemias has been documented, paralleling the more widespread use of dose-intensive therapies and the longer survival of cancer patients. 2 Alkylating agents 3 or more recently, epidophyllotoxinsrelated 4 secondary AML have been described, but also growth factors or different drug combinations seem to affect cellular proliferation, especially in subjects with genetic susceptibility. 5 Because of the effectiveness of chemotherapeutic agents such as topoisomerase II inhibitors (epidophyllotoxins, anthracyclines and their derivates) it is important to define their leukemogenic potential in patients with advanced diseases and mainly in adjuvant regimens for early cancer.
We describe three cases of secondary AML observed in the last year in our Institution, which occurred in women treated with 3M (methotrexate, mitoxantrone, mitomycin) regimen for advanced breast cancer.
Clinical and biologic features are described and the possible relationship between these drugs and the onset of acute leukemia is discussed.
Three women with a history of advanced breast cancer treated with mitoxantrone (8 mg/m 2 intravenously every 3 weeks), mitomycin (8 mg/m 2 intravenously every 6 weeks) and methotrexate (30 mg/m 2 intravenously every 3 weeks) (3M) were admitted in 1996 to our Department for acute leukemia. Clinical characteristics of the patients are shown in Table 1 . Patient No. 1, a 44-year-old woman, was well until 4 years earlier, when breast cancer occurred. She was treated with radical surgery plus six courses of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). One year after the initial diagnosis, she had recurrence of the disease with bone metastases and was treated with six courses of 3M followed by medroxyprogesteron acetate (MAP) and radiation therapy (RT) on the bone lesions. About 6 months from the start of 3M a decrease of white blood cells and platelets count was noted. Eighteen months later she was admitted to our Department because of a hemorrhagic syndrome: the bone marrow examination revealed AML M0 according to FAB criteria. The patient died 4 days later.
Patient No. 2, a 60-year-old woman, had a history of breast cancer treated with radical surgery at 50 years. Six years later, bone metastases developed and she was treated with eight courses of CMF and RT to lesions of the skeleton. At the age of 58, the disease progressed and she was therefore treated with seven courses of 3M followed by MAP. One year after the end of the therapy, piastrinopenia and hemorrhagic syndrome occurred: bone marrow examination disclosed acute promyelocytic leukemia. All-trans retinoic acid therapy was started and at +10 months from diagnosis the patient is alive and well.
Patient No. 3 was a 52-year-old woman. She was well until 10 years earlier when she underwent radical surgery and breast RT for breast cancer. Thirty months before admission, the patient received five courses of 3M followed by tamoxifen for disease recurrence to skeleton and skin. After that a progressive anemia and leucopenia developed: bone marrow examination revealed refractory anemia. Transfusional therapy was prescribed. Two weeks before admission acute monocytic leukemia developed; the patient was treated with Chromosome investigations were carried out at diagnosis on bone marrow samples using direct or short term (24-48 h) culturing techniques. Twenty well-spread GTG banded metaphases were analyzed for each patient.
Patient 1 had normal karyotype; patient 2 was found to have 46,XX,t(15;17)(q22;q12). In patient 3, cytogenetic analysis revealed a complex karyotype interpreted as 45,XX,del(3)(q12.q25), −7,−19,+mar. The chromosome 3 interstitial deletion was confirmed by whole chromosome painting with a digoxygenin-labelled probe specific for chromosome 3 (Oncor, Gaithersburg, MD, USA) that did not show any translocation. Molecular analysis by RT-PCR assay was able to detect fusion transcript PML/RAR alpha (bcr3) in case 2. Southern blot analysis with 0.74 kb MLL cDNA probe to detect MLL gene rearrangements revealed a germline configuration in all three examined cases.
AML occurs in up to 15% of patients treated with cytotoxic drugs, radiation or both. 3 Two different forms of secondary AML are described. The classic one, in patients treated with alkylating agents and/or RT, is characterized by a long latency period (3-5 years), a high incidence of preleukemic phase, frequent cytogenetic abnormalities involving chromosomes 5 and 7 and an extremely poor prognosis. 5 The second form, that occurs in patients who have received agents targeting DNA topoisomerase II, such as epidophyllotoxin derivates (etoposide, teniposide) 4 or anthracyclines and their derivates (such as mitoxantrone) 6 develops after a short latency period (2-3 years), a brief myelodysplastic phase and is associated with myelomonocytic or monocytic morphology. In this form, most cases show a balanced translocation involving chromosome 11q23 leading to rearrangement of MLL gene. This gene encodes a transcription factor with extensive homology to the Drosophila homeotic regulator trithorax and is probably involved in the regulation of differentiation pathway through DNA interaction. 7 Many different mechanisms (aberrant V-D-J recombination, homologous recombination between Alurepeats, and topoisomerase II-mediated non-homologous recombination) 8 seem to be involved in MLL rearrangements, but a genetic susceptibility predisposing this region to altered recombinations cannot be excluded.
Nowadays, detection of molecular MLL rearrangements by Southern blot analysis rather than structural abnormalities of 11q23 (that comprises a heterogeneous group of fusion genes) 9 seems to identify this distinct subtype of secondary AML and to define clinical syndromes and outcome more specifically. 10 Recently, Cremin et al 11 reported a 5% incidence of AML and myelodysplasias after adjuvant chemotherapy for breast cancer using 2M and 3M regimens. Such cases show close similarities with those observed in our Department: a short latency time from therapy, a brief preleukemic phase and a generally poor prognosis; they also showed non-specific cytogenetic abnormalities, but molecular analysis was not reported. In our series, however, Southern blot analysis detected a germline configuration of MLL gene.
Since methotrexate seems to have little leukemogenic potential, 12 the increased risk of AML appears to be probably related to mitoxantrone, alone or by an interaction with mitomycin or methotrexate and/or previous therapies, including RT.
In conclusion, the clinical features of our cases resemble those of secondary AML occurring after treatment with topoisomerase II agents: nevertheless, the lack of MLL rearrangements in our series suggests a different pathway by which cytotoxic drugs and radiations interfere with the genetic program of hemopoietic cells.
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Two months after BMT, cytogenetic and Southern blot analyses were performed and subsequently repeated every 6 months. In all these instances bone marrow cells exhibited a
